The attending physician should pay special attention to the possible appearance of early symptoms of thrombotic disorders (thrombophlebitis, cerebral circulatory disorders, pulmonary embolism and retinal thrombosis). If a symptom is found that indicates these disorders, or even suggests that they are present, the drug should be immediately withdrawn.
Patients with any risk factors for thrombotic disorders should be closely monitored.
In the process of long-term treatment, regular gynecological examinations are necessary in order to exclude the possibility of developing endometrial hyperplasia.
A physical examination before the start of therapy should include an assessment of the condition and development of the mammary glands and pelvic organs, as well as a cervical smear (Papanicolaou test).
In order to prevent the possibility of incomplete abortion in the use of Kraynon®, the level of chorionic gonadotropin should be determined or ultrasound should be performed.
Use with caution in case of liver dysfunction.
In cases of bleeding, such as in all cases of irregular vaginal bleeding, organic pathology should be ruled out.
In the case of vaginal bleeding of unclear etiology, an appropriate examination should be carried out.
Since progestogens have the ability to retain fluid in the body, patients with diseases such as epilepsy, migraine, bronchial asthma, cardiovascular failure, impaired renal function, should be closely monitored.
It is necessary to closely monitor patients who have a history of depression and interrupt treatment if depression worsens.
A small number of patients receiving estrogen-progestagen therapy may experience a decrease in glucose tolerance. The mechanism of this violation is not known.In this regard, patients suffering from diabetes, in the process of treatment with progesterone should be under close supervision.
The preparation Krainon ® includes sorbic acid, which can cause a local skin reaction (contact dermatitis).